Finvest
HOLX Medical technology · Women’s health · Diagnostics · MedTech · Thesis updated June 13, 2026

Hologic’s recovery now rests on execution

01 Running thesis

A cleaner path, not a free pass

Hologic’s story improved in Q3 2025. Revenue of $1.024 billion beat the high end of guidance, and non-GAAP EPS of $1.08 also came in above guidance. More important, the company said it had cut the expected tariff hit to $10 million to $12 million per quarter, about half the prior $20 million to $25 million estimate.

That matters because tariffs were the big new reason earnings guidance had been cut earlier in the year. The smaller hit makes the margin outlook less scary. It also gives management a better chance to hit its longer-term goal of mid-single-digit organic revenue growth and high-single-digit EPS growth.

The bull case is simple. Molecular Diagnostics keeps growing at a steady pace, Breast Health stops falling and starts growing again, and the Envision mammography launch in 2026 gives hospitals a reason to refresh older systems. In Q3, Molecular Diagnostics grew 5.2% excluding COVID, while Breast Health grew sequentially and is expected to return to slight top-line growth in Q4.

The bear case is less dramatic but still real. Tariffs still hurt gross margin, China remains difficult, HIV testing tied to foreign aid is under pressure, and Breast Health depends on hospital capital budgets. If those smaller headwinds pile up, fiscal 2026 growth could land below management’s target.

Jul 2025▲Hologic beat Q3 revenue and EPS guidance and cut the expected tariff hit to $10 million to $12 million per quarter. Breast Health also improved sequentially, with management guiding for slight top-line growth in Q4.
May 2025▼The company lowered full-year non-GAAP EPS guidance after disclosing a new $20 million to $25 million quarterly tariff headwind. China revenue expectations were also cut because of geopolitical and local market pressure.
Feb 2025▼Management lowered full-year revenue guidance by $100 million as Breast Health capital equipment demand weakened. Diagnostics remained strong, but the company became more dependent on that segment to carry fiscal 2025.
Nov 2024→The view centered on solid Diagnostics growth, offset by short-term issues in Skeletal Health and GYN Surgical. Breast Health was still growing at that point, but later hospital replacement delays changed the setup.
02 Business model

Lab platforms and repeat tests

Hologic makes money in four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Diagnostics is the cleanest model. The company places Panther and Panther Fusion instruments in labs, then sells the tests that run on those systems again and again.

That is often called a razor-and-blade model. The instrument is the razor, and the assays are the blades. Once a lab validates a system, switching is hard because it takes money, training, and regulatory work.

Breast Health is more cyclical. It sells 3D mammography systems, software, biopsy tools, and related service. These products can be strong when hospitals replace equipment, but sales can slow when customers stretch replacement cycles.

GYN Surgical sells tools for fibroids, polyps, abnormal bleeding, and vessel sealing. Skeletal Health is smaller and includes bone density systems. The company also plans to stop selling its Fluoroscan Insight FD mini C-arm systems in fiscal 2026, which shows it is trimming weaker product lines.

03 Product portfolio

What Hologic sells

Growth engine

Panther and Panther Fusion diagnostics

These lab systems run molecular tests for infections and women’s health. They create repeat assay sales after a system is installed.

Growth engine

Aptima and Panther Fusion assays

These tests cover areas such as STDs, HPV, viral loads, respiratory infections, and BV/CV/TV. Each new assay can add revenue across the installed Panther base.

Steady

ThinPrep and Genius Digital Diagnostics

These products support cytology testing and digital review. They help keep Hologic tied to women’s health screening workflows.

Cash cow

3D mammography and Breast Health tools

This group includes Selenia Dimensions, 3Dimensions, AI image software, biopsy tools, and localization systems. The near-term question is whether replacement demand returns before Envision launches in 2026.

Steady

MyoSure, NovaSure, and related surgical tools

These products treat fibroids, polyps, and abnormal uterine bleeding with less invasive methods. International growth is helping offset a slower domestic NovaSure market.

Option

Skeletal Health systems

Horizon DXA systems measure bone density and body composition. This is a small segment, and Hologic is discontinuing Fluoroscan Insight FD mini C-arm sales in fiscal 2026.

04 Business segments

Q3 2025 revenue mix

Diagnostics44%modest
Breast Health36%declining
GYN Surgical17%modest
Skeletal Health3%growing fast

The mix uses Q3 2025 segment revenue: Diagnostics $448.9 million, Breast Health $365.2 million, GYN Surgical $178.4 million, and Skeletal Health $31.3 million. Diagnostics and Breast Health made up most of revenue, so those two segments drive the page view.

05 Risk factors

What could still go wrong

Tariffs stay costly

Medium impact · Medium odds

Hologic cut the expected tariff hit to $10 million to $12 million per quarter, but it did not remove it. The company still expects tariffs to be a gross margin headwind in fiscal 2026. If mitigation stalls, EPS growth could miss the high-single-digit goal.

We watchQuarterly tariff impact and gross margin commentary for fiscal 2026.

Breast Health recovery stalls

High impact · Medium odds

Breast Health fell 10.8% organically in Q3 2025, though management expects slight growth in Q4. This business depends on hospitals buying or replacing capital equipment. A weaker hospital spending cycle could delay the recovery and reduce the value of the Envision launch.

We watchOrganic Breast Health growth in Q4 2025 and order commentary for gantry replacements.

China and HIV funding pressure Diagnostics

Medium impact · Medium odds

Diagnostics is the most important growth engine, but not every part is clean. China revenue was down more than 50% year over year in Q3, and a freeze on U.S. foreign aid affects HIV testing in developing countries. These issues could weigh on first-half fiscal 2026 growth.

We watchChina revenue trends and updates tied to PEPFAR or other HIV testing funding.

Surgical growth cannot offset mature products

Medium impact · Medium odds

GYN Surgical grew only 1.2% organically in Q3 2025, despite strong international growth of 24.8%. Domestic NovaSure is in a slow decliner market as alternative therapies grow. Newer products and international sales must carry the segment.

We watchGYN Surgical organic growth and management comments on NovaSure, MyoSure, Sonata, and Acessa.

Regulatory delays slow new products

Medium impact · Low odds

Hologic sells regulated medical devices and diagnostic tests. Many products need FDA clearance, approval, or foreign regulatory clearance. A delay in new assays, Envision, or platform updates would reduce growth options.

We watchFDA or CE-mark updates for Envision, Panther Fusion assays, and other new products.
06 Quick answers

In one breath

What does Hologic do?

Hologic sells medical technology with a focus on women’s health. Its products include diagnostic tests, lab systems, 3D mammography systems, biopsy tools, and minimally invasive surgical devices.

Why is Diagnostics so important to Hologic?

Diagnostics uses a repeat-sales model. Once a lab installs a Panther system, Hologic can keep selling assays that run on that platform.

Why did the Hologic thesis improve in Q3 2025?

The company beat revenue and EPS guidance and reduced the expected tariff hit by about half. Breast Health also showed sequential improvement and is expected to return to slight growth in Q4.

What is the biggest thing to watch next?

Watch Breast Health growth and margin performance in fiscal 2026. Those two items show whether the recovery is becoming real or only delayed.